Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer—Just About Ready for Prime-Time?

As targeted molecular therapies and immuno-oncology have become pivotal in the management of patients with lung cancer, the essential requirement for high throughput analyses and clinical validation of biomarkers has become even more intense, with response rates maintained in the 20%–30% range. More...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancers (Basel)
Главные авторы: Hofman, Paul, Badoual, Cécile, Henderson, Fiona, Berland, Léa, Hamila, Marame, Long-Mira, Elodie, Lassalle, Sandra, Roussel, Hélène, Hofman, Véronique, Tartour, Eric, Ilié, Marius
Формат: Artigo
Язык:Inglês
Опубликовано: MDPI 2019
Предметы:
Review
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6468415/
https://ncbi.nlm.nih.gov/pubmed/30818873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11030283
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы